Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Healthcare Shares
Mesoblast share price rockets 36% on breaking FDA news
Healthcare Shares
Guess which ASX All Ords company is being sued by shareholders over stock price losses
Share Gainers
4 ASX All Ords shares going gangbusters on Tuesday
Share Gainers
Why 4DMedical, Block, Judo, and Mesoblast shares are pushing higher today
Share Market News
Why is the Mesoblast share price jumping 16% on Monday?
Share Fallers
Why Cettire, GQG, Mesoblast, and Nine Entertainment shares are falling today
Earnings Results
Mesoblast share price tumbles on US$32.5m half-year loss
Healthcare Shares
Guess which ASX 300 healthcare stock is surging 13% on FDA news
Share Gainers
Why EML, Jumbo, Mesoblast, and Whitehaven Coal shares are jumping today
Healthcare Shares
Why are Mesoblast shares rocketing 28% today?
Share Gainers
Why Arcadium Lithium, Core Lithium, Fortescue, and Mesoblast shares are pushing higher
Share Gainers
Why Fortescue, Mesoblast, Temple & Webster, and Virgin Money shares are rising
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
